SNAP-8
/ Synthetic acetylated octapeptide; INCI 'Acetyl Octapeptide-3'; SNARE complex / SNAP-25 mimicALIAS · SNAP-8 (trade) · Acetyl Octapeptide-3 (INCI)
Terms in this page you can click for a plain-English popup: , , , , , , , .
Tier 4. SNAP-8 is the trade name for Acetyl Octapeptide-3, an extended (eight-residue) variant of the better-known Argireline (Acetyl Hexapeptide-3 / -8). Marketed by Lipotec / Lubrizol as a topical SNARE-complex inhibitor mimetic. The mechanistic class is well-established in vitro; topical-efficacy claims in cosmetic application rest predominantly on industry-authored studies.
The proposed mechanism is competitive mimicry of the N-terminal end of SNAP-25, one of three core proteins of the SNARE (Soluble NSF Attachment Protein REceptor) complex that mediates synaptic vesicle fusion at the neuromuscular junction. By binding the SNARE assembly site, the synthetic octapeptide is claimed to interfere with neurotransmitter (acetylcholine) release and thereby attenuate facial mimetic-muscle contraction. SNAP-8 is the eight-residue extension of Argireline's six-residue parent; the extension is asserted to confer higher SNARE-binding affinity. Whether topical application achieves meaningful concentration at the underlying neuromuscular junction is the primary translational question, and is not well-characterised in independent published work.
Tier 4. Industry comparison studies position SNAP-8 as more potent than Argireline in cell-based wrinkle-depth proxies. Independent randomised topical-efficacy trials versus placebo at supplier-recommended concentrations are sparse in the indexed primary literature.
No formal independent safety database beyond supplier patch-test data. Systemic exposure from topical application is presumed low. Theoretical class concern: the SNARE-complex mechanism is the molecular target of botulinum toxin type A (which cleaves SNAP-25); the cosmetic mimetic's potency is asserted to be far below clinical thresholds, but independent confirmation is limited.
Regulatory status
- FDA status:
- Not FDA-approved
Vendor marketing routinely positions SNAP-8 as an enhanced Argireline. Industry studies supporting the comparison were authored by suppliers with commercial interest. Argireline itself has more substantial published characterisation than SNAP-8; readers should not transfer Argireline efficacy claims to SNAP-8 without specific supporting evidence.